[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"chronic-kidney-disease-stage-1\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:chronic-kidney-disease-stage-1":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":32,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":41,"lastUpdatePostDateStruct":42,"startDateStruct":45,"completionDateStruct":47,"leadSponsor":49,"locationsCount":5},"100616706","clinical-morphometric-and-biochemical-effects-on-adiposopathy-associated-with-the-use-of-glp-1ra-in-ckd-100616706",false,"NCT07309094","Clinical, Morphometric and Biochemical Effects on Adiposopathy Associated With the Use of GLP-1RA in CKD","Clinical, Morphometric and Biochemical Effects on Adiposopathy Associated With the Use of GLP-1 Receptor Agonists in Chronic Kidney Disease","ADIPO-CKD","Inclusion Criteria:\n\n* \\> or = 18 years of age\n* diagnosed with CKD in stages G1, G2, G3a, G3b, and G4, not candidate for dialysis\n* had uncontrolled T2DM, CVDs and\u002For obesity\n* willing to participate in the study and sign informed consent\n\nExclusion Criteria:\n\n* Age \\\u003C18 years\n* pregnancy\n* CKD in stage G5 or G4 candidate for dialysis\n* neuropsychiatric diseases preventing the patient from understanding the benefits\u002Frisks associated with the project\n* refusal to participate and\u002For consent revocation were considered as exclusion criteria","ALL","18 Years","90 Years",{"count":21,"type":22},250,"ESTIMATED","OBSERVATIONAL","Chronic kidney disease (CKD) is the progressive damage to kidney function, associated with an increased risk of cardiovascular diseases, such as stroke or myocardial infarct, particularly in the most severe stages of CKD, in which the patient requires dialysis. Several risk factors are reported for CKD, such as diabetes mellitus, obesity and hypertension. One of the most increasingly recognized risk factors is the fat tissue malfunction, known as adiposopathy. The accumulation of fat tissue around the organs in conditions of obesity or diabetes accelerates the production of pro-inflammatory factors that may worsen the kidney and heart damage. New antidiabetic medications, such as glucagon-like peptide-1 receptor agonists (GLP-1RA), have proven beneficial effects on the kidney and heart due to several mechanisms, including anti-inflammatory actions and a potential action on the fat tissue.\n\nThe aim of this study is to assess the link between adiposopathy and CKD, by investigating the changes in adiposopathy measures throughout treatment with GLP-1RA to a sample of patients with CKD.",[26,27,28,29,30,31],"Chronic Kidney Disease stage3","Chronic Kidney Disease stage4","Chronic Kidney Disease Stage 1","Chronic Kidney Disease Stage 2","Obesity","Diabetes Mellitus, Type 2",[33,34,35,36,37,38,39],"chronic kidney disease","type 2 diabetes mellitus","GLP-1RA","adiposopathy","perivisceral adipose tissue","perirenal adipose tissue","inflammation","RECRUITING","2025-12-15",{"date":43,"type":44},"2025-12-30","ACTUAL",{"date":46,"type":44},"2023-09-15",{"date":48,"type":22},"2028-12-31",{"name":50,"class":51},"Cardenal Herrera University","OTHER"]